Business
RVX-208 Leads to a 77% Relative Risk Reduction of Major Adverse Cardiovascular Events (MACE) in Patients with Diabetes Mellitus
Presented in 'State of the Art and Featured Research Session' at the 2014 European Society...
About this update from Resverlogix Corp.
[{"type":"text","content":"\n\n\nPresented in 'State of the Art and Featured Research Session' at the\n 2014 European Society of Cardiology Congress \n\n\nTSX Exchange Symbol: RVX\n\n\nBARCELONA, Spain and CALGARY, AB, Sept. 2, 2014 /CNW/ - Resverlogix\n Corp. (TSX: RVX) announced today that Dr. Jan Johansson, senior vice\n president of medical affairs at Resverlogix delivered an oral\n presentation at the 2014 European Society of Cardiology (ESC) Congress\n in Barcelona, Spain. In his presentation, entitled: 'Effects of RVX-208 on MACE, ApoA-I and HDLs; a post-hoc analysis from\n the pooled SUSTAIN and ASSURE clinical trials', Dr. Johansson reported that patients with cardiovascular disease\n (CVD) arising from atherosclerosis when given RVX-208 had a 55%\n (p=0.02) relative risk reduction (RRR) in MACE. More importantly, this\n beneficial effect of RVX-208 on patients with diabetes mellitus was\n accentuated with a RRR in MACE that was lowered by 77% (p=0.01). These\n observed reductions in MACE may stem from the ability of RVX-208 to\n significantly improve specific biomarkers of CVD risk measured in the\n SUSTAIN and ASSURE trials, including: higher levels of ApoA-I protein\n (p<0.01), an increase in HDL-C (p<0.001), more large HDL-particles\n (p<0.05) and growth in HDL particle size (p<0.05). The significant\n improvement in these biomarkers was in treated patients vs. placebo,\n which point to the beneficial effects of RVX-208 on reverse cholesterol\n transport.\n\n\nRVX-208 acts via an epigenetic pathway and it is the first selective BET\n inhibitor being studied for treatment of CVD. The new information\n contained in the ESC presentation arose from the analysis of data\n pooled from the ASSURE and SUSTAIN clinical trials.\n\n\n\"The above findings are valuable to Resverlogix because they put the\n company in an advantageous position in the emerging field of\n therapeutics based on BET inhibition,\" said Dr. Norman C.W. Wong, chief\n scientific officer of Resverlogix and also a practicing\n endocrinologist. \"The data enhances the potential for RVX-208 to lower\n MACE in CVD patients and especially in those with diabetes mellitus.\n These key pieces of information will be used for the design of our next\n clinical trial that will continue the development of RVX-208 towards\n product registration.\"\n\n\nDonald McCaffrey, president...